You have no items in your cart.
Grants of $4.6M to Support Trials of Cancer Therapy in Early Alzheimer’s
The National Institute of Aging (NIA) and the Alzheimer’s Drug Discovery Foundation (ADDF) have awarded $4.6 million to a team of researchers studying the potential of the cancer therapy Revlimid (lenalidomide) in treating people with early stage Alzheimer’s disease. Two clinical trials, each supported by one of these grants, are planned. The first is now recruiting up to 30 eligible adults at its single site in Nevada. The $3.2 million grant from the NIA — a branch…